Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-23

FDA Approved: ENJAYMO — Supplemental Application (Recordati Rare Diseases, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENJAYMO (sutimlimab-jome) filed by Recordati Rare Diseases, Inc., approving changes described in the supplemental su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enjaymo (sutimlimab)

Snippet

SUPPL AP for ENJAYMO (SUTIMLIMAB-JOME)